The UK Rapid Test Consortrium’s rapid covid-19 antibody test has been shown to detect antibodies (igG) for up to 140 days following the first symptoms or a positive PCR test result.
This revelations comes following the recent trials of the rapid COVID-19 test conducted by Ulster University.
An article at medRxiv, the preprint server for health sciences owned by BMJ and Yale University details results from the trial.
Crucially, the test shown a specificity of 100% and sensitivity of 97.7% (95.72%-99.34%) as highlighted from an extract from the respective source titled ‘SARS-CoV-2 antibody testing in a UK population: detectable IgG for up to 20 weeks post infection.’:
“The UK-RTC AbC-19 lateral flow immunoassay using shows a sensitivity of 97.70% (95.72%-99.34%) and specificity of 100% (100.00-100.00%).”
The test was also compared to other lab-based igG tests from the likes of Roche, Abbott and Euroimmun.
It is known the MHRA requires a specificity of greater than 98% for rapid antibody tests which adds weight to the likelihood of Omega Diagnostics and the UK RTC receiving the approval needed for home-use of the antibody test. However, with 97.7% sensitivity the question mark remains if it will meet the adjacent sensitivity MHRA guidelines that are also greater than 98%.